Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection
NCT ID: NCT00004422
Last Updated: 2015-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
174 participants
INTERVENTIONAL
1997-08-31
2002-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Assess the efficacy of a single infusion of a high titer pertussis immune globulin for the treatment of severe pertussis in children.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine
NCT01188512
Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
NCT02453048
Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand
NCT02408926
A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants
NCT02145624
Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants
NCT01890850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients are followed every 2 weeks for up to 6 months.
Completion date provided represents the completion date of the grant per OOPD records
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
immune globulin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IWK Health Centre
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott A. Halperin
Role: STUDY_CHAIR
IWK Health Centre
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IWK-FDR001044
Identifier Type: -
Identifier Source: secondary_id
P9701
Identifier Type: -
Identifier Source: secondary_id
199/13322
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.